NCT04913220 2026-02-04
A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)
Sanofi
Phase 1/2 Terminated
Clinical Trials
8 trialsNCT06052852 2025-11-17
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
Phase 1 Terminated
NCT04982224 2025-11-03
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer
Regeneron Pharmaceuticals
Phase 1 Terminated
NCT03769181 2025-09-23
A Study of Isatuximab-based Therapy in Participants With Lymphoma
Sanofi
Phase 1/2 Terminated
NCT03871348 2025-09-10
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sanofi
Phase 1 Terminated
NCT04006119 2025-04-18
Study of Ad-RTS-hIL-12 + Veledimex in Combination With Cemiplimab in Subjects With Recurrent or Progressive Glioblastoma
Alaunos Therapeutics
Phase 2 Terminated
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT04382898 2025-03-20
PRO-MERIT
BioNTech SE
Phase 1/2 Terminated